Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy

Autor: Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada, Toshihide Yokoyama, Takehiko Kobayashi, Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, Ryota Nakamura, Yuki Katayama, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Thoracic Cancer, Vol 15, Iss 26, Pp 1882-1888 (2024)
Druh dokumentu: article
ISSN: 1759-7714
1759-7706
DOI: 10.1111/1759-7714.15416
Popis: Abstract Background Advances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor prognosis. To date, the prognosis of LC complicated by CPA has not been elucidated. This study investigated the clinical implications of concomitant CPA in patients with LC undergoing anticancer drug treatment. Methods Between January 2010 and May 2020, we consecutively enrolled patients with LC complicated with CPA at five different institutions in Japan. We analyzed patients with LC complicated by CPA who received anticancer drug treatment. Results A total of 10 patients with LC complicated by CPA received anticancer drug treatment. The median overall survival (OS) was 14.57 months (95% confidence interval [CI]: 5.37–21.67). The cause of death in all patients was LC. Six of the seven patients with LC did not show worsening pulmonary aspergillosis lesions during the anticancer drug treatment. Although two patients discontinued anticancer drug treatment due to pneumonitis, CPA complications did not interfere with the continuation of anticancer drug treatment. In univariate analyses, squamous histology (p = 0.01) and body mass index (
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje